TD Cowen analyst Daniel Brennan has maintained their neutral stance on ILMN stock, giving a Hold rating on July 28.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Daniel Brennan’s rating is based on Illumina’s strong performance in a challenging market environment, where the company exceeded revenue expectations and demonstrated robust margins. Despite these positive results, the stock’s recent significant increase in value may limit further short-term gains, leading to a more cautious outlook.
Moreover, while Illumina’s management has been effective in setting realistic expectations and executing strategic initiatives, the ongoing transition to new technologies and the potential risks associated with new product developments and market dynamics suggest a balanced approach. The conservative guidance on earnings per share and the uncertainties surrounding future growth, particularly in clinical consumables, further support the Hold rating.
Brennan covers the Healthcare sector, focusing on stocks such as Bruker, Illumina, and Thermo Fisher. According to TipRanks, Brennan has an average return of 10.1% and a 46.59% success rate on recommended stocks.
In another report released on July 28, Robert W. Baird also maintained a Hold rating on the stock with a $105.00 price target.